AU2020218267A1 - TYK2 pseudokinase ligands - Google Patents
TYK2 pseudokinase ligands Download PDFInfo
- Publication number
- AU2020218267A1 AU2020218267A1 AU2020218267A AU2020218267A AU2020218267A1 AU 2020218267 A1 AU2020218267 A1 AU 2020218267A1 AU 2020218267 A AU2020218267 A AU 2020218267A AU 2020218267 A AU2020218267 A AU 2020218267A AU 2020218267 A1 AU2020218267 A1 AU 2020218267A1
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutically acceptable
- compound
- solvate
- acceptable salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802642P | 2019-02-07 | 2019-02-07 | |
| US62/802,642 | 2019-02-07 | ||
| PCT/US2020/017314 WO2020163778A1 (en) | 2019-02-07 | 2020-02-07 | Tyk2 pseudokinase ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020218267A1 true AU2020218267A1 (en) | 2021-09-30 |
Family
ID=71947508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020218267A Abandoned AU2020218267A1 (en) | 2019-02-07 | 2020-02-07 | TYK2 pseudokinase ligands |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220135567A1 (https=) |
| EP (1) | EP3920931A4 (https=) |
| JP (1) | JP2022519696A (https=) |
| KR (1) | KR20210124409A (https=) |
| CN (1) | CN113677347A (https=) |
| AU (1) | AU2020218267A1 (https=) |
| BR (1) | BR112021015616A2 (https=) |
| CA (1) | CA3129438A1 (https=) |
| IL (1) | IL285429A (https=) |
| MX (1) | MX2021009555A (https=) |
| SG (1) | SG11202108619SA (https=) |
| WO (1) | WO2020163778A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019364336B2 (en) | 2018-10-22 | 2023-11-16 | Alumis Inc. | TYK2 inhibitors and uses thereof |
| AU2020247990A1 (en) | 2019-03-26 | 2021-11-11 | Ventyx Biosciences, Inc. | TYK2 pseudokinase ligands |
| KR102938141B1 (ko) | 2019-11-08 | 2026-03-11 | 벤틱스 바이오사이언스, 인크. | Tyk2 슈도키나제 리간드 |
| AU2021345181A1 (en) * | 2020-09-16 | 2023-05-04 | Alumis Inc | Tyk2 inhibitors and uses thereof |
| CN117043164A (zh) * | 2021-01-19 | 2023-11-10 | 安锐生物医药科技(广州)有限公司 | 咪唑并哒嗪或吡唑并嘧啶化合物和组合物 |
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
| WO2025061180A1 (zh) * | 2023-09-22 | 2025-03-27 | 杭州多域生物技术有限公司 | 含氮并环类化合物、其药物组合物及其应用 |
| WO2025165746A1 (en) * | 2024-01-30 | 2025-08-07 | Ennovathera, Inc. | Certain chemical entities, compositions, and methods |
| WO2025168035A1 (zh) * | 2024-02-07 | 2025-08-14 | 合肥羿科医药有限公司 | 杂环类化合物、其药物组合物及其应用 |
| WO2025214467A1 (zh) * | 2024-04-12 | 2025-10-16 | 江苏恒瑞医药股份有限公司 | 氨基取代的杂芳环类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4564485B2 (ja) * | 2003-02-28 | 2010-10-20 | 帝人ファーマ株式会社 | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| CN102271515B (zh) * | 2008-10-31 | 2014-07-02 | 健泰科生物技术公司 | 吡唑并嘧啶jak抑制剂化合物和方法 |
| US10479793B2 (en) * | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| TW201720828A (zh) * | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| JP7160824B2 (ja) * | 2017-03-08 | 2022-10-25 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤、使用およびその製造のための方法 |
| CN110678467B (zh) * | 2017-05-22 | 2023-06-13 | 豪夫迈·罗氏有限公司 | 治疗化合物和组合物及其使用方法 |
| KR102717819B1 (ko) * | 2017-07-28 | 2024-10-14 | 다케다 야쿠힌 고교 가부시키가이샤 | Tyk2 억제제 및 이의 용도 |
| JP7179161B2 (ja) * | 2018-09-10 | 2022-11-28 | イーライ リリー アンド カンパニー | 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体 |
| JP7619951B2 (ja) * | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| TWI800696B (zh) * | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
| KR102938141B1 (ko) * | 2019-11-08 | 2026-03-11 | 벤틱스 바이오사이언스, 인크. | Tyk2 슈도키나제 리간드 |
-
2020
- 2020-02-07 US US17/428,953 patent/US20220135567A1/en not_active Abandoned
- 2020-02-07 BR BR112021015616A patent/BR112021015616A2/pt not_active Application Discontinuation
- 2020-02-07 KR KR1020217028660A patent/KR20210124409A/ko not_active Ceased
- 2020-02-07 EP EP20752194.9A patent/EP3920931A4/en not_active Withdrawn
- 2020-02-07 JP JP2021546005A patent/JP2022519696A/ja active Pending
- 2020-02-07 AU AU2020218267A patent/AU2020218267A1/en not_active Abandoned
- 2020-02-07 CA CA3129438A patent/CA3129438A1/en active Pending
- 2020-02-07 MX MX2021009555A patent/MX2021009555A/es unknown
- 2020-02-07 SG SG11202108619SA patent/SG11202108619SA/en unknown
- 2020-02-07 CN CN202080026979.3A patent/CN113677347A/zh active Pending
- 2020-02-07 WO PCT/US2020/017314 patent/WO2020163778A1/en not_active Ceased
-
2021
- 2021-08-08 IL IL285429A patent/IL285429A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3920931A1 (en) | 2021-12-15 |
| US20220135567A1 (en) | 2022-05-05 |
| SG11202108619SA (en) | 2021-09-29 |
| CA3129438A1 (en) | 2020-08-13 |
| BR112021015616A2 (pt) | 2021-11-09 |
| MX2021009555A (es) | 2021-10-13 |
| EP3920931A4 (en) | 2022-08-10 |
| IL285429A (en) | 2021-09-30 |
| JP2022519696A (ja) | 2022-03-24 |
| CN113677347A (zh) | 2021-11-19 |
| KR20210124409A (ko) | 2021-10-14 |
| WO2020163778A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020218267A1 (en) | TYK2 pseudokinase ligands | |
| JP7595582B2 (ja) | Ｔｙｋ２偽キナーゼリガンド | |
| KR102938141B1 (ko) | Tyk2 슈도키나제 리간드 | |
| AU2020314186B2 (en) | NLRP3 modulators | |
| EP3999496B1 (en) | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as nlpr3 modulators for the treatment of multiple sclerosis (ms) | |
| KR102916168B1 (ko) | Jak 억제제 | |
| AU2020354629A1 (en) | JAK inhibitors | |
| US20230312589A1 (en) | Jak inhibitors | |
| WO2023137353A1 (en) | 15-pgdh inhibitors | |
| HK40066192A (zh) | Tyk2假激酶配体 | |
| HK40066192B (zh) | Tyk2假激酶配体 | |
| HK40064378A (en) | Tyk2 pseudokinase ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |